Table 2 Treatment characteristics- Patients receiving SCT
Patients ≥ 60 years of age | Patients 61–65 years of age | |
|---|---|---|
N (%) | N (%) | |
Induction treatment | ||
VAD | 90 (42,6) | 32 (39,5) |
Cy/Dex | 120 (56,5) | 49 (60,5) |
Vel/Dex | 2 (0,9) | 0 |
Consolidation | ||
IFN | 38 (17,9) | 10 (12,3) |
Bortezomib | 25 (11,9) | 7 (8,6) |
No consolidation | 149 (70,2) | 64 (79,1) |
Treatment response | ||
Progressive disease | 1 (0,6) | 3 (3,6) |
Stable disease | 7 (3,2) | 1 (1,2) |
Minimal response | 9 (4,2) | 2 (2,4) |
Partial response | 102 (48,1) | 49 (59.0) |
Complete response | 57 (27,2) | 19 (22,9) |
Not evaluable | 36 (16,7) | 9 (10,9) |